QBFM
ACOR

QS Batterymarch Financial Management’s Acorda Therapeutics ACOR Stock Holding History

QS Batterymarch Financial Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-59
Closed -$208K – 1165
2013
Q4 		$208K Hold
59
– – ﹤0.01% 869
2013
Q3 		$243K Hold
59
– – 0.01% 828
2013
Q2 		$235K Buy
+59
New +$243K ﹤0.01% 838

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QS Batterymarch Financial Management's ACOR Position: Q1 2014 in Review

QS Batterymarch Financial Management sold out of Acorda Therapeutics (ACOR) in Q1 2014, closing a stake of 59 shares — an estimated $208K sold.

QS Batterymarch Financial Management first reported a position in ACOR in Q2 2013 and held it in 3 quarters. The position peaked at $243K in Q3 2013. 152 funds tracked by Wall St. Rank hold ACOR as of Q1 2014.

  • QS Batterymarch Financial Management reported no remaining Acorda Therapeutics position as of Q1 2014 after selling out during the quarter.
  • QS Batterymarch Financial Management sold 59 Acorda Therapeutics shares in Q1 2014, an estimated $208K.
  • QS Batterymarch Financial Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 3 quarters.
  • QS Batterymarch Financial Management's Acorda Therapeutics position peaked at $243K in Q3 2013.
  • 152 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2014.

Based on QS Batterymarch Financial Management's 13F filing for Q1 2014, filed 15 May 2014.